AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38622543 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Vision Therapy Group (new near glasses with accommodative and convergence eye exercises)
Number of subjects: 150
Study 38622543 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism Group (near prismatic glasses prescribed using Sheard's criterion)
Number of subjects: 150
Study 38622543 — intervention group
Group type: COMPARATOR
Intervention: Control Group (new near glasses and aimless eye movement exercises)
Number of subjects: 150
Study 38622593 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital at Home (HaH-HA)
Number of subjects: 441
Study 38622593 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 441
Study 38622608 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring of spirometry
Number of subjects: 60
Study 38622608 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring of pulse oximetry
Number of subjects: 60
Study 38622608 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly monitoring by clinical teams
Number of subjects: 60
Study 38622608 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience questionnaire for remote measurements
Number of subjects: 60
Study 38622629 — intervention group
Group type: COMPARATOR
Intervention: No preheating (control group at room temperature)
Number of subjects: 105
Study 38622629 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite preheated once
Number of subjects: 105
Study 38622629 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite preheated ten cycles
Number of subjects: 105
Study 38622634 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Imagery (MI) training, 10 min per day, 5 days per week
Number of subjects: 19
Study 38622634 — intervention group
Group type: COMPARATOR
Intervention: Neutral cognitive exercises (control group), 10 min per day, 5 days per week
Number of subjects: 19
Study 38622655 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning labels only
Number of subjects: 3518
Study 38622655 — intervention group
Group type: EXPERIMENTAL
Intervention: Tax only
Number of subjects: 3518
Study 38622655 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined warning labels + tax
Number of subjects: 3518
Study 38622655 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3518
Study 38622671 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-guided intraoperative fluid replacement therapy with lactated Ringer's solution (n = 31)
Number of subjects: 60
Study 38622671 — intervention group
Group type: COMPARATOR
Intervention: Unbalanced 6% hydroxyethyl starch 130/0.4 (n = 29)
Number of subjects: 60
Study 38622729 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to a 6-min educational video 5 days after discharge from the hospital.
Number of subjects: 0
Study 38622729 — intervention group
Group type: COMPARATOR
Intervention: No access to the educational video (Control group).
Number of subjects: 0
Study 38622759 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate
Number of subjects: 0
Study 38622759 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38622766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium-Glucose Cotransporter 2 Inhibitors
Number of subjects: 0
Study 38622766 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or standard care)
Number of subjects: 0
Study 38622840 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab added to lenalidomide, bortezomib, and dexamethasone (D-RVd)
Number of subjects: 0
Study 38622840 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide, bortezomib, and dexamethasone (RVd)
Number of subjects: 0
Study 38622879 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin 1.8 mg/kg once every 3 weeks with R-CHP for six cycles
Number of subjects: 0
Study 38622879 — intervention group
Group type: COMPARATOR
Intervention: R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisone)
Number of subjects: 0
Study 38622893 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 104
Study 38622893 — intervention group
Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 104
Study 38623494 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based titration of levodopa duodenal infusions (LCIG)
Number of subjects: 12
Study 38624067 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular cigarette
Number of subjects: 64
Study 38624067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 38624150 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Dressing (CD)
Number of subjects: 0
Study 38624150 — intervention group
Group type: COMPARATOR
Intervention: No Compression Dressing (Control)
Number of subjects: 0
Study 38625480 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients
Number of subjects: 733
Study 38625671 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 279
Study 38625671 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 279
Study 38625671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 38625721 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention for HIV risk reduction
Number of subjects: 159
Study 38625721 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous tablet use
Number of subjects: 159
Study 38625721 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous smartphone use
Number of subjects: 159
Study 38625721 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting homelessness
Number of subjects: 159
Study 38625721 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting unemployment
Number of subjects: 159
Study 38625721 — intervention group
Group type: EXPERIMENTAL
Intervention: Current school enrollment
Number of subjects: 159
Study 38625721 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity
Number of subjects: 159
Study 38625729 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person recruitment for patients
Number of subjects: 382
Study 38625729 — intervention group
Group type: COMPARATOR
Intervention: Remote recruitment for patients (telehealth, email, telephone)
Number of subjects: 382
Study 38625729 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person recruitment for providers
Number of subjects: 382
Study 38625729 — intervention group
Group type: COMPARATOR
Intervention: Remote recruitment for providers
Number of subjects: 382
Study 38625800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten (CAMZYOS), dosage and duration not available
Number of subjects: 0
Study 38625800 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38625912 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported screening tool (NRS 2002) at home
Number of subjects: 215
Study 38625912 — intervention group
Group type: COMPARATOR
Intervention: In-hospital assessments by healthcare professionals (NRS 2002)
Number of subjects: 215
Study 38625984 — intervention group
Group type: EXPERIMENTAL
Intervention: Tabelecleucel
Number of subjects: 26
Study 38626079 — intervention group
Group type: EXPERIMENTAL
Intervention: PiCSO-assisted pPCI
Number of subjects: 145
Study 38626079 — intervention group
Group type: COMPARATOR
Intervention: Conventional pPCI
Number of subjects: 145
Study 38626080 — intervention group
Group type: EXPERIMENTAL
Intervention: Short dual antiplatelet therapy (DAPT)
Number of subjects: 5232
Study 38626363 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (target range 80-130 mg/dL)
Number of subjects: 725
Study 38626363 — intervention group
Group type: COMPARATOR
Intervention: Standard sliding scale (80-179 mg/dL)
Number of subjects: 725
Study 38626363 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (intensive insulin vs standard sliding scale)
Number of subjects: 725
Study 38626363 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-thrombolysis hyperglycemia
Number of subjects: 725
Study 38626553 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That HEAL (CTH) intervention in Wave 1 communities
Number of subjects: 67
Study 38626553 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted Wave 2 communities
Number of subjects: 67
Study 38626807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 1 HRIs underwent germline testing and pancreas imaging by MRI/MR-cholangiopancreatography or endoscopic ultrasound.
Number of subjects: 3402
Study 38626807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 1 HRIs with familial pancreatic cancer (FPC)
Number of subjects: 3402
Study 38626807 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 1 HRIs with pathogenic germline variant and familial pancreatic cancer (PGV+/FPC+)
Number of subjects: 3402
Study 38626807 — intervention group
Group type: COMPARATOR
Intervention: Cohort 1 HRIs with pathogenic germline variant without familial pancreatic cancer (PGV+/FPC-)
Number of subjects: 3402
Study 38626807 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age as a predictor
Number of subjects: 3402
Study 38626940 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR tools and expedited referral workflow for IDA
Number of subjects: 316
Study 38626940 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 316
Study 38626956 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio campaign promoting responsive caregiving and opportunities for early learning during the first 3 years of life.
Number of subjects: 250000000
Study 38626956 — intervention group
Group type: COMPARATOR
Intervention: Not available.
Number of subjects: 250000000
Study 38626961 — intervention group
Group type: EXPERIMENTAL
Intervention: New WHO Labour Care Guide (LCG)
Number of subjects: 520
Study 38626961 — intervention group
Group type: COMPARATOR
Intervention: Historical cohort using the partograph
Number of subjects: 520
Study 38626958 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB (Bexsero) vaccine
Number of subjects: 0
Study 38626958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38626967 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphaticovenous anastomosis (LVA) operation
Number of subjects: 110
Study 38626967 — intervention group
Group type: COMPARATOR
Intervention: Sham surgery
Number of subjects: 110
Study 38626974 — intervention group
Group type: EXPERIMENTAL
Intervention: Training cohort data used to train algorithms
Number of subjects: 5000
Study 38626974 — intervention group
Group type: COMPARATOR
Intervention: Validation cohort data used to validate algorithms
Number of subjects: 5000
Study 38626975 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable sutures
Number of subjects: 0
Study 38626975 — intervention group
Group type: COMPARATOR
Intervention: Non-absorbable sutures
Number of subjects: 0
Study 38626982 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory syncytial virus (RSV) and other respiratory viruses
Number of subjects: 3000
Study 38626982 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired serum samples for RSV antibodies
Number of subjects: 3000
Study 38626982 — intervention group
Group type: COMPARATOR
Intervention: Clinical outcomes assessment
Number of subjects: 3000
Study 38626982 — intervention group
Group type: COMPARATOR
Intervention: Readmission and all-cause mortality data collection
Number of subjects: 3000
Study 38627035 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor administered at 60 mg weekly as maintenance therapy
Number of subjects: 220
Study 38627035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 38627114 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation exercise (15 min daily for 4 weeks)
Number of subjects: 75
Study 38627114 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 75
Study 38627137 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative beta-blockers
Number of subjects: 10272
Study 38627238 — intervention group
Group type: EXPERIMENTAL
Intervention: Derazantinib monotherapy (300 mg QD in Substudy 1, 200 mg BID in Substudy 5)
Number of subjects: 49
Study 38627238 — intervention group
Group type: EXPERIMENTAL
Intervention: Derazantinib 300 mg QD plus atezolizumab 1200 mg every 3 weeks (Substudy 2)
Number of subjects: 49
Study 38627238 — intervention group
Group type: EXPERIMENTAL
Intervention: Derazantinib 200 mg BID plus atezolizumab 1200 mg every 3 weeks (Substudy 3)
Number of subjects: 49
Study 38627238 — intervention group
Group type: EXPERIMENTAL
Intervention: Derazantinib 300 mg QD monotherapy (Substudy 4)
Number of subjects: 49
Study 38627238 — intervention group
Group type: EXPERIMENTAL
Intervention: Derazantinib 300 mg QD plus atezolizumab 1200 mg every 3 weeks (Substudy 4)
Number of subjects: 49
Study 38627266 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT) - 10,000 lx; daily 30-min sessions for 10 weeks
Number of subjects: 207
Study 38627266 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise intervention (EI) - aerobic and muscle-strengthening activities 3 days/week for 10 weeks
Number of subjects: 207
Study 38627266 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 207
Study 38627366 — intervention group
Group type: EXPERIMENTAL
Intervention: TQ-B3525, 20 mg orally once daily in a 28-day cycle
Number of subjects: 107
Study 38627377 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-1 blockade plus stereotactic body radiotherapy (SBRT)
Number of subjects: 20
Study 38627377 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant tislelizumab
Number of subjects: 20
Study 38627631 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg)
Number of subjects: 21
Study 38627631 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calcium tablet)
Number of subjects: 21
Study 38627668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 0.15 mg/kg
Number of subjects: 70
Study 38627668 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 70
Study 38627686 — intervention group
Group type: EXPERIMENTAL
Intervention: TapTalk smartphone test
Number of subjects: 1382
Study 38627712 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Bioactive Trabecular Coating (SBTC®)
Number of subjects: 20
Study 38627712 — intervention group
Group type: COMPARATOR
Intervention: Control group (commercial electrochemical surface treatment)
Number of subjects: 20
Study 38627712 — intervention group
Group type: EXPERIMENTAL
Intervention: SBTC®
Number of subjects: 20
Study 38627712 — intervention group
Group type: COMPARATOR
Intervention: Both groups (SBTC® and Control)
Number of subjects: 20
Study 38627722 — intervention group
Group type: EXPERIMENTAL
Intervention: A. annua plus M. oleifera
Number of subjects: 282
Study 38627722 — intervention group
Group type: EXPERIMENTAL
Intervention: A. annua
Number of subjects: 282
Study 38627722 — intervention group
Group type: COMPARATOR
Intervention: Routine standard of care only
Number of subjects: 282
Study 38627795 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship intervention (including voluntary continuing medical education for primary care physicians, distribution of written guidelines, implementation of project homepage, onsite training for nursing staff)
Number of subjects: 326
Study 38627795 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 326
Study 38627795 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship intervention
Number of subjects: 326
Study 38627795 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 326
Study 38627799 — intervention group
Group type: EXPERIMENTAL
Intervention: SAIA-TB intervention
Number of subjects: 16
Study 38627819 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed implant-retained mandibular overdentures (IMO)
Number of subjects: 26
Study 38627819 — intervention group
Group type: COMPARATOR
Intervention: Traditional denture manufacturing methods
Number of subjects: 26
Study 38627819 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed IMO
Number of subjects: 26
Study 38627823 — intervention group
Group type: EXPERIMENTAL
Intervention: ECPR-based approach (intra-arrest transport, ECPR if ROSC is not achieved prehospital and immediate invasive assessment)
Number of subjects: 256
Study 38627823 — intervention group
Group type: COMPARATOR
Intervention: CCPR (conventional CPR)
Number of subjects: 256
Study 38627823 — intervention group
Group type: EXPERIMENTAL
Intervention: ECPR-based approach
Number of subjects: 256
Study 38627823 — intervention group
Group type: COMPARATOR
Intervention: CCPR
Number of subjects: 256
Study 38627837 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 sessions of individual schema therapy
Number of subjects: 129
Study 38627837 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (mainly group-based, short-term cognitive behaviour or psychodynamic therapy)
Number of subjects: 129
Study 38627843 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-Child Assistance Program (PCAP)
Number of subjects: 200
Study 38627843 — intervention group
Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 200
Study 38627850 — intervention group
Group type: EXPERIMENTAL
Intervention: Online compassion-based self-help intervention for depression (6 weeks with email support)
Number of subjects: 34
Study 38627850 — intervention group
Group type: EXPERIMENTAL
Intervention: Online compassion-based self-help intervention for depression
Number of subjects: 34
Study 38628080 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender-focused HIV risk-reduction intervention
Number of subjects: 500
Study 38628080 — intervention group
Group type: COMPARATOR
Intervention: HIV testing
Number of subjects: 500
Study 38628260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 43
Study 38628260 — intervention group
Group type: COMPARATOR
Intervention: Group analyses
Number of subjects: 43
Study 38628315 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 38
Study 38628315 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 38
Study 38628555 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic group (bupropion or varenicline based on genetic markers)
Number of subjects: 361
Study 38628555 — intervention group
Group type: COMPARATOR
Intervention: Control group (varenicline treatment)
Number of subjects: 361
Study 38628675 — intervention group
Group type: EXPERIMENTAL
Intervention: Various approaches to create an effective anti-HIV-1 vaccine
Number of subjects: 40100000
Study 38628675 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunogen presentation modalities
Number of subjects: 40100000
Study 38629062 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 Ad5-nCoV adenovirus vaccine
Number of subjects: 69
Study 38629062 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 69
Study 38629273 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA patency detected by cardiac computed tomography angiography at 3 months post-LAA closure
Number of subjects: 519
Study 38629273 — intervention group
Group type: COMPARATOR
Intervention: Complete closure of LAA
Number of subjects: 519
Study 38629286 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinus Rhythm (SR)
Number of subjects: 1240
Study 38629286 — intervention group
Group type: COMPARATOR
Intervention: No AF recorded during follow-up
Number of subjects: 1240
Study 38629312 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 2591
Study 38629403 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 0
Study 38629403 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Therapy
Number of subjects: 0
Study 38629416 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 10872
Study 38629416 — intervention group
Group type: COMPARATOR
Intervention: No LV recovery (control group)
Number of subjects: 10872
Study 38629416 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with no previous myocardial infarction (MI) and mean aortic valve gradient (mAVG) >40 mmHg
Number of subjects: 10872
Study 38629416 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with baseline LV function (EF) >30%
Number of subjects: 10872
Study 38629420 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography-guided coronary revascularisation strategy
Number of subjects: 320
Study 38629420 — intervention group
Group type: COMPARATOR
Intervention: Physiology-guided coronary revascularisation strategy
Number of subjects: 320
Study 38629508 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma eligibility screening
Number of subjects: 4905
Study 38629508 — intervention group
Group type: EXPERIMENTAL
Intervention: PET eligibility screening
Number of subjects: 4905
Study 38629811 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (initial bolus 0.23 mg/kg, continuous infusion 0.58 mg/kg/hr)
Number of subjects: 40
Study 38629811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 38630086 — intervention group
Group type: EXPERIMENTAL
Intervention: MR elastography liver stiffness measurement
Number of subjects: 0
Study 38630086 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38630186 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary furlow palatoplasty with buccal myomucosal flap (FPBF)
Number of subjects: 23
Study 38630259 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU plus mobile phone intervention
Number of subjects: 120
Study 38630259 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 120
Study 38630259 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 120
Study 38630297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutured AMIC
Number of subjects: 47
Study 38630297 — intervention group
Group type: COMPARATOR
Intervention: MFx
Number of subjects: 47
Study 38630457 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg subcutaneously every 4 weeks for 12 weeks
Number of subjects: 30
Study 38630471 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics monotherapy (moxifloxacin, 400 mg/d for 7 days)
Number of subjects: 582